Combination of CD95/CD95L inhibition and Cancer Immunotherapy
First Claim
Patent Images
1. Combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent for use in the treatment of cancer.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the treatment of cancer using a combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent, e.g. a cancer vaccine or a checkpoint inhibitor. Another aspect of the invention is the prognosis of responsiveness of a cancer to the treatment with a combination of a CD95 inhibitor and an immunotherapeutic agent. Further disclosed are preparations and kits for use in these methods.
14 Citations
20 Claims
- 1. Combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent for use in the treatment of cancer.
-
17. A pharmaceutical composition or kit comprising
(i) an inhibitor of the CD95/CD95L signaling system, and (ii) an immunotherapeutic agent selected.
-
19. A method of predicting responsiveness of a cancer disease to the treatment with a combination of a CD95L inhibitor and an immunotherapeutic agent, the method comprising
(a) determining the expression of CD95L in a cancer sample, (b) classifying the cancer disease according the level of CD95L expression, (c) optionally determining the expression of a target molecule of the immunotherapeutic agent in said cancer sample and classifying the cancer disease according to the expression level of said target molecule, (d) determining if the type of cancer that has been classified can be treated with a combination of a CD95L inhibitor and an immunotherapeutic agent, and optionally carrying out the treatment.
Specification